A phase I, open-label, dose-finding study to evaluate the safety and pharmacokinetics of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, in patients with advanced solid tumours.

Trial Profile

A phase I, open-label, dose-finding study to evaluate the safety and pharmacokinetics of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, in patients with advanced solid tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2015

At a glance

  • Drugs ONX 0801 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 31 Mar 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 28 Sep 2009 Onyx Pharmaceuticals has announced the initiation of this trial in a company media release.
    • 01 Jul 2009 Planned initiation date (30 Sep 2009), planned end date (30 Mar 2011), planned number of patients (60), official title, trial locations and lead trial centers and investigator added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top